Design of Experiments in the Formulation and Optimization of Sustained Release Matrix Tablets: A Review

Oral drug delivery remains the most widely accepted and preferred route of administration due to its convenience, patient compliance, cost-effectiveness, and ease of large-scale manufacturing. However, conventional immediate-release dosage forms often require frequent dosing to maintain therapeutic plasma concentrations, leading to poor patient adherence and increased risk of dose-related side effects. To overcome these limitations, sustained release (SR) drug delivery systems have been extensively developed with the objective of maintaining drug concentrations within the therapeutic window for prolonged periods while minimizing dosing frequency and plasma level fluctuations [1,2]. Among the various sustained release systems, matrix tablets have gained significant attention due to their simplicity of formulation, reproducibility, stability, and suitability for industrial manufacturing. In matrix systems, the drug is uniformly dispersed within a polymeric matrix that controls drug release primarily through diffusion, erosion, or a combination of both mechanisms [3,4]. Commonly used matrix formers include hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), sodium alginate, xanthan gum, and natural gums, as well as hydrophobic polymers like ethylcellulose and waxes. Despite their advantages, the development of sustained release matrix tablets is inherently complex due to the involvement of multiple formulation and process variables that simultaneously influence drug release behavior, mechanical strength, swelling characteristics, and overall tablet performance. Variables such as polymer type and concentration, drug solubility, particle size, compression force, excipient compatibility, and manufacturing conditions often interact in a nonlinear manner, making formulation optimization challenging when using conventional trial-and-error approaches [5]. Traditionally, pharmaceutical formulation development relied on the one-factor-at-a-time (OFAT) approach, where a single variable is changed while keeping others constant. Although simple, this method is time-consuming, resource-intensive, and incapable of identifying interaction effects between variables. As a result, OFAT often leads to sub-optimal formulations and limited scientific understanding of the formulation space [6]. These limitations have driven the adoption of more systematic and statistically robust approaches for formulation development. In this context, Design of Experiments (DoE) has emerged as a powerful and indispensable tool in pharmaceutical research and development. DoE is a structured, multivariate statistical methodology that enables simultaneous evaluation of multiple formulation and process factors and their interactions on critical quality attributes (CQAs) of the dosage form [7]. By applying DoE, formulators can efficiently screen significant variables, build predictive mathematical models, and optimize formulations with a minimal number of experimental runs. The application of DoE in sustained release matrix tablet formulation has been extensively reported in the literature (Table 1-3). Studies have demonstrated its effectiveness in optimizing polymer concentration, drug-to-polymer ratio, and compression parameters to achieve desired release kinetics and mechanical properties [8,9]. Response surface methodology (RSM) designs such as Central Composite Design (CCD) and Box–Behnken Design (BBD) have been particularly valuable in developing quadratic models that describe complex release behavior and enable visualization through contour and three-dimensional surface plots [10,11]. Furthermore, the integration of DoE aligns closely with the Quality by Design (QbD) paradigm advocated by regulatory agencies such as the US Food and Drug Administration (FDA) and the International Council for Harmonisation (ICH). According to ICH Q8(R2), pharmaceutical development should be based on sound scientific principles and risk-based approaches, with DoE playing a central role in defining design space and ensuring consistent product quality [12]. In sustained release formulations, DoE facilitates a deeper understanding of how formulation variables affect drug release mechanisms, thereby supporting regulatory flexibility and lifecycle management. Recent research has also highlighted the role of DoE in elucidating mechanistic aspects of matrix systems, such as polymer hydration, gel layer formation, erosion dynamics, and diffusion pathways [13]. This mechanistic insight not only aids in optimization but also enhances the predictability and robustness of sustained release formulations under scale-up and manufacturing variations. Therefore, this review aims to provide a comprehensive overview of the application of Design of Experiments in the formulation and optimization of sustained release matrix tablets (Figure 1). Emphasis is placed on experimental design strategies, selection of critical formulation variables, statistical analysis, and practical examples from original research studies, highlighting the indispensable role of DoE in modern pharmaceutical formulation development.

Table 1: Common Design of Experiments (DoE) approaches employed in the formulation and optimization of sustained release matrix tablets [14]